A 779
目录号 : GC11004
A Mas receptor antagonist
Cas No.:159432-28-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Animal experiment: |
A bilateral OVX operation is use to induce postmenopausal osteoporosis in female Wistar albino rats. The animals are generally anesthetized using single IP injection of ketamine + xylazine combination (80 mg/kg and 5 mg/kg; respectively). After ligation, the ovaries are excised from a longitudinal incision made on the dorsolateral body region. Sham rats have the same procedure without the ligation and excision. The risk of postoperative infection is eliminated by applying fusidic acid topical antibiotic cream twice weekly for 4 weeks. Following the sham and OVX operations, animals are divided into eight groups (n = 8/group) including, Sham, Sham + Ang(1-7), Sham + A-779, Sham + Ang(1-7)+A-779, OVX, OVX + Ang(1-7), OVX + A-779 and OVX + Ang(1-7)+A-779. Eight weeks following sham and OVX operations, osmotic pumps are implanted subcutaneously to deliver Ang(1-7) (200 ng/kg/min), A-779 (400 ng/kg/min) or a mixture of Ang(1-7) and A-779 (200 ng/kg/min and 400 ng/kg/min; respectively) for 6 consecutive weeks. Body weights of all animals are monitored and recorded at the beginning and every week throughout the study. Animals' general health is maintained during periods of treatments. At the end of treatments periods, animals are placed fasting in metabolic cages for 16 hr and urine samples are collected and frozen at −70°C. Then, the blood samples are collected by cardiac puncture under ketamine + xylazine anesthesia and serum samples are obtain by centrifugation at 4000 RPM to. Animals are then sacrificed by decapitation and the uterine tissues and femoral bones are removed and cleaned. Uterine tissues are cleaned from fats and the wet weights are determined directly and expressed as g/100 g body weight. In each rat, both femurs are removed and cleaned from soft tissues. The left femoral bone samples are frozen at −70°C until analyzed, while the right femoral bones are kept in 10% formalin for mico-CT and minerals analysis. |
|
References: [1]. Abuohashish HM, et al. Angiotensin (1-7) ameliorates the structural and biochemical alterations of ovariectomy-induced osteoporosis in rats via activation of ACE-2/Mas receptor axis. Sci Rep. 2017 May 23;7(1):2293. |
|
A 779 is a potent and selective angiotensin-(1-7)/ Mas receptor antagonist [1].
Angiotensin-(1-7) is a bioactive component of the renin angiotensin system (RAS) which plays an important role in cardiovascular homeostasis and hydroelectrolyte balance in physiological and pathologic conditions [1][2].
A 779 is an angiotensin antagonist selective for the heptapeptide angiotensin-(I-7) [Ang-(l-7)] [1].
In water-loaded rats, A 779 significantly inhibited the antidiuretic effect of Ang-(l-7). In the rostral ventrolateral medulla, A-779 completely blocked the pressor effect produced by Ang-(1-7) microinjection [1]. In conscious Wistar rats, infusion of vehicle or A-779 (80 ng/ min, i.v.) started 40 to 45 minutes after captopril administration produced a significant shift of the BK dose-response curve obtained after captopril. A-779 significantly attenuated the potentiation of the hypotensive effect of BK by the ACE inhibitor captopril in conscious rats [2]. In anaesthetized male Wistar rats, when AT1R and AT2R were blocked, A779 increased renal blood flow/wet kidney tissue weight (RBF/KW). Co-blockade of all AT1R, AT2R, and MasR might alter RBF/ KW in male more than in female rats, which supported a crosstalk between MasR and Ang II receptors in renal circulation [3].
References:
Santos RA, Campagnole-Santos MJ, Baracho NC, et al. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull. 1994;35(4):293-8.
Maia LG, Ramos MC, Fernandes L, et al. Angiotensin-(1-7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J Cardiovasc Pharmacol. 2004 May;43(5):685-91.
Mansoori A, Oryan S, Nematbakhsh M. Role of Mas receptor antagonist (A779) in renal hemodynamics in condition of blocked angiotensin II receptors in rats. Acta Physiol Hung. 2016 Mar;103(1):13-20.
| Cas No. | 159432-28-7 | SDF | |
| 化学名 | (2R,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17S,18Z,20S)-5-((1H-imidazol-5-yl)methyl)-20-amino-8-((S)-sec-butyl)-17-(3-guanidinopropyl)-4,7,10,13,16,19-hexahydroxy-11-(4-hydroxybenzyl)-14-isopropyl-2-methyl-3,6,9,12,15,18-hexaazadocosa-3,6,9,12,15,18-hexaene-1,22- | ||
| Canonical SMILES | CC[C@]([C@@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](N)([H])CC(O)=O)([H])CCCNC(N)=N)([H])C(C)C)([H])CC1=CC=C(O)C=C1)([H])/C(O)=N/[C@@](/C(O)=N/[C@](C(O)=O)([H])C)([H])CC2=CN=CN2)([H])C | ||
| 分子式 | C39H60N12O11 | 分子量 | 872.97 |
| 溶解度 | ≥ 29.1mg/mL in Water with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1455 mL | 5.7276 mL | 11.4551 mL |
| 5 mM | 0.2291 mL | 1.1455 mL | 2.291 mL |
| 10 mM | 0.1146 mL | 0.5728 mL | 1.1455 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。